Clinical Trial

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2026-11-30 -> 2026-10-30 2026-08-15
notable Primary completion pushed: 2026-07-30 -> 2026-11-30 2026-08-05
minor Completion pushed: 2026-07-30 -> 2026-11-30 2026-08-05
Trial Details
NCT Number NCT05853575
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Enrollment 200 participants
Start Date 2024-02-01
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14